232 related articles for article (PubMed ID: 3091770)
1. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.
Leenders KL; Palmer AJ; Quinn N; Clark JC; Firnau G; Garnett ES; Nahmias C; Jones T; Marsden CD
J Neurol Neurosurg Psychiatry; 1986 Aug; 49(8):853-60. PubMed ID: 3091770
[TBL] [Abstract][Full Text] [Related]
2. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
[TBL] [Abstract][Full Text] [Related]
3. Seasonality of striatal dopamine synthesis capacity in Parkinson's disease.
Kaasinen V; Jokinen P; Joutsa J; Eskola O; Rinne JO
Neurosci Lett; 2012 Nov; 530(1):80-4. PubMed ID: 23041046
[TBL] [Abstract][Full Text] [Related]
4. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography in movement disorders.
Martin WR
Can J Neurol Sci; 1985 Feb; 12(1):6-10. PubMed ID: 3156662
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptors in Parkinson's disease.
Hassan MN; Thakar JH
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(2-3):173-82. PubMed ID: 3290993
[TBL] [Abstract][Full Text] [Related]
7. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
8. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
Indo T
Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
[No Abstract] [Full Text] [Related]
9. Cerebral uptake and utilization of therapeutic [beta-11C]-L-DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response.
Tedroff J; Aquilonius SM; Hartvig P; Bredberg E; Bjurling P; Långström B
Acta Neurol Scand; 1992 Feb; 85(2):95-102. PubMed ID: 1574995
[TBL] [Abstract][Full Text] [Related]
10. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
11. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
[TBL] [Abstract][Full Text] [Related]
12. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
[TBL] [Abstract][Full Text] [Related]
13. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography.
Leenders KL; Poewe WH; Palmer AJ; Brenton DP; Frackowiak RS
Ann Neurol; 1986 Aug; 20(2):258-62. PubMed ID: 3092728
[TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
16. Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?
Stoessl AJ
Mov Disord; 2001 Sep; 16(5):804-6. PubMed ID: 11746608
[No Abstract] [Full Text] [Related]
17. [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study.
Kuten J; Linevitz A; Lerman H; Freedman N; Kestenbaum M; Shiner T; Giladi N; Even-Sapir E
J Integr Neurosci; 2020 Sep; 19(3):489-494. PubMed ID: 33070528
[TBL] [Abstract][Full Text] [Related]
18. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
19. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
20. PET studies and motor complications in Parkinson's disease.
Brooks DJ
Trends Neurosci; 2000 Oct; 23(10 Suppl):S101-8. PubMed ID: 11052227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
